CL2021002309A1 - Compuestos útiles en la terapia del vih - Google Patents

Compuestos útiles en la terapia del vih

Info

Publication number
CL2021002309A1
CL2021002309A1 CL2021002309A CL2021002309A CL2021002309A1 CL 2021002309 A1 CL2021002309 A1 CL 2021002309A1 CL 2021002309 A CL2021002309 A CL 2021002309A CL 2021002309 A CL2021002309 A CL 2021002309A CL 2021002309 A1 CL2021002309 A1 CL 2021002309A1
Authority
CL
Chile
Prior art keywords
useful compounds
hiv therapy
compounds
hiv
therapy
Prior art date
Application number
CL2021002309A
Other languages
English (en)
Inventor
La Rosa Martha Alicia De
John F Miller
David Temelkoff
Emile Johann Velthuisen
B Narasimhulu Naidu
Vicente Samano
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of CL2021002309A1 publication Critical patent/CL2021002309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con compuestos de Fórmula (I), sales de los mismos, composiciones farmacéuticas de los mismos, además de métodos para tratar o prevenir VIH en sujetos.
CL2021002309A 2019-03-06 2021-09-03 Compuestos útiles en la terapia del vih CL2021002309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
CL2021002309A1 true CL2021002309A1 (es) 2022-09-20

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002309A CL2021002309A1 (es) 2019-03-06 2021-09-03 Compuestos útiles en la terapia del vih

Country Status (21)

Country Link
US (3) US20230174534A1 (es)
EP (1) EP3934760A1 (es)
JP (1) JP2022525013A (es)
KR (1) KR20210136052A (es)
CN (1) CN113811360A (es)
AR (1) AR118240A1 (es)
AU (1) AU2020231934B2 (es)
BR (1) BR112021017604A2 (es)
CA (1) CA3132112A1 (es)
CL (1) CL2021002309A1 (es)
CO (1) CO2021012579A2 (es)
CR (1) CR20210460A (es)
EA (1) EA202192433A1 (es)
IL (1) IL285894A (es)
MA (1) MA55200A (es)
MX (1) MX2021010700A (es)
PE (1) PE20212089A1 (es)
SG (1) SG11202109253SA (es)
TW (1) TW202102233A (es)
WO (1) WO2020178767A1 (es)
ZA (1) ZA202106096B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164528A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
US20240317754A1 (en) * 2020-12-30 2024-09-26 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
US11890297B2 (en) 2021-01-25 2024-02-06 Brii Biosciences, Inc. Combination therapy for HIV with adenosine derivative and capsid inhibitors
US20240182510A1 (en) * 2021-02-23 2024-06-06 Viiv Healthcare Company Compounds Useful in HIV Treatment
WO2024163262A2 (en) * 2023-01-30 2024-08-08 Merck Sharp & Dohme Llc Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR20030093248A (ko) 2001-03-19 2003-12-06 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170313735A1 (en) * 2014-10-31 2017-11-02 Sandoz Ag Improved Fluorination Process
CA2998646C (en) * 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2018085307A1 (en) * 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy

Also Published As

Publication number Publication date
SG11202109253SA (en) 2021-09-29
AU2020231934B2 (en) 2023-04-20
EP3934760A1 (en) 2022-01-12
AR118240A1 (es) 2021-09-22
KR20210136052A (ko) 2021-11-16
AU2020231934A8 (en) 2022-03-24
CO2021012579A2 (es) 2021-10-20
US20220411425A1 (en) 2022-12-29
WO2020178767A1 (en) 2020-09-10
JP2022525013A (ja) 2022-05-11
CN113811360A (zh) 2021-12-17
US20240182473A1 (en) 2024-06-06
IL285894A (en) 2021-10-31
TW202102233A (zh) 2021-01-16
MX2021010700A (es) 2021-10-01
CR20210460A (es) 2022-02-03
AU2020231934A1 (en) 2021-09-23
CA3132112A1 (en) 2020-09-10
EA202192433A1 (ru) 2021-12-28
US20230174534A1 (en) 2023-06-08
BR112021017604A2 (pt) 2021-11-16
PE20212089A1 (es) 2021-11-04
MA55200A (fr) 2022-01-12
ZA202106096B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2019002204A1 (es) Compuestos inhibidores del vih.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды